BIONXT SOLUTIONS ACQUIRES NOVEL PRECISION DRUG COATING AND DELIVERY TECHNOLOGY
Mar 7, 2023
VANCOUVER, BC – March 07, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...
BIONXT SIGNS CLINICAL STUDY AGREEMENT AND COMMENCES MANUFACTURE OF CLINICAL SAMPLES FOR STUDY OF TRANSDERMAL ROTIGOTINE PATCH FOR PARKINSON’S DISEASE
Mar 1, 2023
VANCOUVER, BC – March 1, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...
BIONXT REPORTS UPDATE ON COMMERCIALIZATION OF ROTIGOTINE PATCH FOR TREATMENT OF PARKINSON’S DISEASE
Feb 13, 2023
VANCOUVER, BC – February 13, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...
XPhyto reports excellent Rotigotine in-vitro/ex-vivo results for Parkinson’s disease treatment
Oct 18, 2022
Vancouver, Canada, and Uttenweiler, Germany (October 18, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...
XPhyto completes Rotigotine transdermal patch optimization and comparative skin absorption study
Oct 11, 2022
Vancouver, Canada, and Uttenweiler, Germany (October 11, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...
XPhyto Signs Letter of Intent for US Manufacturing and Strategic Business Opportunities
Oct 5, 2022
Vancouver, Canada, and Uttenweiler, Germany (October 4, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...
XPhyto Files Patent Application for Library of Novel Psychedelic Compounds
Sep 20, 2022
Vancouver, Canada, and Uttenweiler, Germany (September 20, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...
XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease
Jul 18, 2022
Vancouver, Canada, and Uttenweiler, Germany (July 18, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...
Prof. Dr. Raimar Loebenberg receives Leadership Award from the Canadian Society for Pharmaceutical Sciences
Jun 27, 2022
Vancouver, Canada, and Uttenweiler, Germany (June 27, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to congratulate...
XPhyto adds pharmaceutical manufacturing expert Dr. Florian A. Sahr to its European team
Jun 8, 2022
Vancouver, Canada, and Uttenweiler, Germany (June 8, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report...
XPhyto reports product developments on platform-based Rotigotine transdermal patch for Parkinson’s disease
May 9, 2022
Vancouver, Canada, and Uttenweiler, Germany (May 9, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...
XPhyto, Biosensors market and product developments on platform-based oral dissolvable biosensors for oral health and infectious disease
Apr 12, 2022
Vancouver, Canada, and Uttenweiler, Germany (April 11, 2022) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to provide...
